Jinwon Life Sciences Subsidiary VGXI Holds Topping-Out Ceremony for New Production Facility Under Construction in Conroe, USA

[Asia Economy Reporter Jang Hyowon] Jinwon Life Sciences announced on the 20th that VGXI, a subsidiary and a cGMP (current Good Manufacturing Practice) contract development and manufacturing organization (CDMO) company, held a topping-out ceremony hosted by the construction company BE&K Building Group as the final steel beam was erected, completing the framework of the new production facility under construction in Conroe, Texas, USA.

The company explained that the construction of the state-of-the-art production facility currently underway on a 21.5-acre site located in Deison Technology Park is progressing in phases, with the first phase expected to be completed in the fourth quarter of this year and operational in the first quarter of next year.

They also stated, "To align with the global plasmid contract manufacturing industry outlook and to promote VGXI's growth, we have an option to secure an additional 21-acre production site."

Aerial view of the new production facility of VGXI, a subsidiary of Jinwon Life Sciences.

Park Younggeun, CEO of Jinwon Life Sciences, said, "We have successfully achieved an important milestone for the construction of VGXI’s headquarters and new production facility," adding, "This plant, designed to have expanded production capacity, flexibility, and specialized capabilities, will fully satisfy our clients through VGXI’s skilled technology and commitment to quality."

He further added, "There is no doubt that once VGXI’s new production facility is completed, it will become a global leader in the cGMP plasmid manufacturing sector."

This content was produced with the assistance of AI translation services.